Matinas BioPharma Holdings, Inc. (MTNB)
NYSEAMERICAN: MTNB · IEX Real-Time Price · USD
0.157
-0.004 (-2.18%)
Jul 2, 2024, 4:00 PM EDT - Market closed
MTNB Revenue
In the year 2023, Matinas BioPharma Holdings had annual revenue of $1.10M, a decrease of -65.62%.
Revenue (ttm)
$1.10M
Revenue Growth
-65.62%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
32
Market Cap
39.43M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.10M | -2.09M | -65.62% |
Dec 31, 2022 | 3.19M | 3.16M | 9,560.61% |
Dec 31, 2021 | 33.00K | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Inotiv | 552.74M |
Atara Biotherapeutics | 34.70M |
Ocuphire Pharma | 19.01M |
electroCore | 18.69M |
Co-Diagnostics | 6.68M |
Lipocine | 4.71M |
Lucid Diagnostics | 2.98M |
OncoCyte | 1.38M |
MTNB News
- 8 days ago - Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program - GlobeNewsWire
- 19 days ago - Matinas BioPharma's Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. - GlobeNewsWire
- 6 weeks ago - New In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024 - GlobeNewsWire
- 7 weeks ago - Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update - GlobeNewsWire
- 2 months ago - Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024 - GlobeNewsWire
- 3 months ago - Matinas BioPharma Prices $10 Million Registered Direct Offering - GlobeNewsWire
- 3 months ago - Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update - GlobeNewsWire
- 3 months ago - Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation - GlobeNewsWire